

---

Curriculum Vitae

**Paris P. Bransford, M.D.**

4390 Sterling Lane / Beaumont, TX 77706 / (409) 898-0205

---

Present Position:

**Southeast Texas Cardiology Associates II, L.L.P.**

2693 North Street

Beaumont, Texas 77702

(409) 832-8862 (409) 835-5132 Fax

**Southeast Texas Clinical Research Center**

2680 McFaddin Avenue

Beaumont, Texas 77702

(409) 839-4003 (409) 839-8469 fax

**EDUCATION**

- 7/94-6/95 Georgetown University Hospital, Washington, D.C.  
Electrophysiology Fellowship
- 1/94-6/95 Veterans Affairs Hospital, Washington, D.C.  
Research Assistant in the Lab of Janice Jones, Ph.D.
- 7/93-12/93 Georgetown University Hospital, Washington, D.C.  
Medicine Residency
- 7/90-6/93 Georgetown University Hospital, Washington, D.C.  
Cardiology Fellowship
- 1/88-6/88 Veterans Administration Hospital, Washington, D.C.  
Medicine Internship
- 7/88-6/90 Medicine Residency
- 7/87-12/87 Howard University Hospital, Washington, D.C.  
Surgery Internship
- 7/83-6/87 University of Texas Medical Branch, Galveston, Texas
- 9/79-12/82 Vanderbilt University, Nashville, TN  
Bachelor of Science – Cum Laude Graduate  
Major: Biology - Minor: Chemistry

## AWARDS & HONORS

- 1992 Mamie Doud Eisenhower Award, American Heart Association  
\$18,000.00 Fellowship for research support(12 months)
- 1987 Herman A. Barnett Award of Surgery and Anesthesia, UTMB
- 1999 Memorial Hermann Baptist Healthcare System  
Doctor of the Year

## PUBLICATIONS

### Manuscripts

**Correlations Between Shock Induced Response Duration And Success of Defibrillation.** Oscar H. Tovar, M.D., Paris P. Bransford, M.D., Jean B. Moubarak, M.D., Kevin B. Milne M.S.E.E., Ashwin E. Amanna M.S.E.E., and Janice L. Jones, Ph.D. *Proc IEEE Eng Med Biol Soc* 1994;15.

**Probability of Induction and Stabilization of Ventricular Fibrillation with Epinephrine.** Tovar O, Bransford PP, Jones JL. *J Mol Cell Cardiol* 1998;30:373-382.

### Abstracts

**Epinephrine Reduces Ventricular Fibrillation Threshold and Stabilizes Fibrillation by Reducing Cellular Refractory Period During Fibrillation.** Paris P. Bransford, P. Jacob Varghese, Oscar H. Tovar, Kevin B. Milne, Janice L. Jones. *Pacing Clin Electrophysiol* 1993;16:866

**Epinephrine Facilitates Fibrillation by Shortening Action Potential Duration and Refractory Period at VT/Fibrillation Cycle Lengths.** Oscar H. Tovar, Kevin B. Milne, Paris P. Bransford, P. Jacob Varghese, Ronald E. Jones, Janice L. Jones. *Pacing Clin Electrophysiol* 1993;16:866

**Mechanisms of Spontaneous Defibrillation in the Rabbit Heart.** P. Jacob Varghese, Paris P. Bransford, Oscar H. Tovar, Kevin B. Milne, Janice L. Jones. *JACC* 1993;21 (2) 306A.

**Recording with Single Optical Fiber Systems and Cooled CCD Imager.** V.Krauthamer, Ph.D; J.L. Jones, Ph.D; O. Tovar, M.D.; P. Bransford, M.D.; A.E. Amanna, B.S.; C.C. Davis, Ph.D.  
*Proc. AAMI/NHLBI Cardiovascular Science and Technology Section 12/1993; pg. 39*

**Shock Induced Response Duration and Type of Successful Defibrillation.** Tovar O, Bransford P.P., Moubarak, J.B., Milne K.B., Amanna A.E., Jones J.L. Abstract. Presented at American Heart Association Meeting, November 1994.

**Extension of Refractoriness and Probability of Successful Defibrillation.** Tovar O, Moubarak J.B., Bransford P.P., Milne K.B., Amanna A.E., Jones J.L. Abstract. Presented at American Heart Association Meeting, November 1994.

#### **PROFESSIONAL SOCIETIES**

Association of Black Cardiologists  
American College of Cardiology, Associate Fellow  
American Heart Association  
American Medical Association  
Jefferson County Medical Society  
North American Society of Pacing and Electrophysiology

#### **LECTURES**

2/1991 Pathophysiology and treatment of cardiomyopathy  
3/1992 History and theory of electric counter shock  
8/1992 Basic mechanisms of epinephrine's effect on the monophasic action potential  
9/1996 Mechanisms and treatment of SVT

- 10/1996      Introducing to ECG analysis
- 3/1997      Electrocardiographic analysis of acute myocardial infarction
- 4/1997      Treatment of Ventricular Tachycardia
- 3/1999      Use of IV Amiodarone for Ventricular Tachycardia  
(Beaumont and Tyler, Texas)
- 7/1999      Symposium on Supraventricular Tachycardia Mechanisms and  
Treatment included intracardiac electrograms and pharmacology
- 9/1999      Diagnosis and Management of SVT (St. Elizabeth Hospital)

**PRESENTATIONS**

- 5/1993      North American Society of Pacing and Electrophysiology,  
Abstract Presentation

**CLINICAL EXPERIENCE**

- 8/95-8/97      The Heart Center of East Alabama, Opelika, AL.  
Cardiac Electrophysiology
- 10/97-Present      Southeast Texas Cardiology Associates, Beaumont, Texas.  
Cardiac Electrophysiology

**CERTIFICATIONS**

- 1994      ABIM, Internal Medicine, Board Certified
- 1997      ABIM, Cardiovascular Diseases, Board Certified
- 1998      ABIM, Clinical Cardiac Electrophysiology, Board Certified

**CLINICAL INTERESTS**

Implantation of Brady pacing devices  
Implantation of implantable cardiac defibrillators  
Ablation of supraventricular tachycardia  
Diagnostic electrophysiology studies  
Cardiac mapping  
Tilt table studies  
Temporary pacing  
Diagnostic coronary angiography  
Diagnostic left heart catheterization  
Diagnostic right heart catheterization  
Transseptal puncture to left atrium with/without TEE guidance  
(for left-sided pathways)

**CLINICAL RESEARCH**

|                   |  |
|-------------------|--|
| 5/1/2002 - 2005   | Pfizer - Lipitor/ Norvasc<br>Protocol # A3841012<br>Gemini Study – Sub-Investigator                              |
| 8/2002 – 2005     | Aventis – Acute Coronary Syndrome Study<br>Protocol XRP4563B/4001<br>Rescue ACS Study – Principal Investigator   |
| 12/2003 – 12/2006 | Otsuka Maryland Research Institute<br>Protocol 156-03-236<br>Acute Decompensated – CHF Study<br>Sub-Investigator |
| 12/2004 – 2006    | Guidant<br>CRT Renewal Registry<br>Principal Investigator  |
| 1/2006 –          | St. Jude Medical<br>ACT Registry<br>ICD Registry   |
| 1/2006 –          | St. Jude Medical<br>PAS Registry<br>Device Performance Registry  |

**CLINICAL RESEARCH CONTINUED**

|                  |  |
|------------------|--|
| 12/2006 – 5/2009 | Reliant Pharmaceuticals – Omacor<br>Protocol OM8 afib<br>Recurrent, Symptomatic atrial fibrillation                  |
| 9/2006-9/2007    | Pfizer – Caduet<br>Protocol A3841046<br>HTN and Hyperlipidemia<br>Sub-Investigator                                   |
| 7/2004-12/2006   | Pfizer – torceptrapib / atorvastatin<br>Protocol A5091043<br>Hypercholesterolemia and CV events<br>Sub-Investigator  |
| 12/2005-9/2007   | AstraZeneca – Rosuvastatin / Atorvastatin<br>Protocol 4522US/001<br>ACS<br>Sub-Investigator                          |
| 8/2006 – 4/2009  | Amgen, Inc. – Darbepoetin Alfa<br>Protocol 20050222<br>Heart Failure and Anemia<br>Sub-Investigator                  |
| 10/2005 – 2007   | Lilly – Prasugrel and ASA vs. Clopidogrel and ASA<br>Protocol H7T-MC-TAAL<br>ACS<br>Sub-Investigator                 |
| 2/2006 – 6/2009  | Amgen, Inc. – Darbepoetin Alfa<br>Protocol 20010184<br>Diabetes, CKD, and anemia<br>Sub-Investigator                 |
| 6/2006 – 12/2006 | Palatin Technologies – PT-141<br>Protocol PT-141-2006-32<br>HTN safety for ED drug<br>Sub-Investigator               |
| 8/2006 – 6/2008  | Novartis – Diovan and Lotrel<br>Protocol CVAL483AUS62<br>Observational Study for BP<br>Sub-Investigator              |
| 2006 – Present   | Johnson & Johnson – Rivaroxiban and Coumadin<br>Protocol 9039039 AFL3001<br>Atrial Fibrillation<br>Sub-Investigator. |

**CLINICAL RESEARCH CONTINUED**

|                   |   |
|-------------------|---|
| 12/2006 – Present | Pfizer – Celebrex, Naproxen and Aleve<br>Protocol A3191172<br>Osteoarthritis and Rheumatoid Arthritis<br>Sub-Investigator       |
| 2006 – 6/2009     | Reliant – Omacor<br>Protocol OM8<br>Atrial Fibrillation<br>Primary Investigator   |
| 2006 – 6/2009     | Gilead – Darusentan and Guanfacine<br>Protocol DAR312<br>Resistant Hypertension<br>Sub-Investigator                             |
| 3/2007 – 12/2008  | Merck – Exetimibe and Atorvastatin<br>Protocol 112-01<br>Hypercholesterolemia<br>Sub-Investigator                               |
| 5/2008 – 01/2009  | Cogentus – Clopidogrel and CGT-2168<br>Protocol CG104<br>Reduce GI Events and Bleeding<br>Sub-Investigator                      |
| 11/2008 – 6/2009  | Bristol Myers Squibb/ Pfizer – Apixiban<br>Protocol CV185057<br>Deep Vein Thrombosis and Pulmonary Embolism<br>Sub-Investigator |
| 02/2009 – 2009    | Roche – dalcetapib<br>Protocol NC20971C<br>Hypercholesterolemia<br>Sub-Investigator   |
| 04/2010 -         | Novartis – enalapril – ACE /NEP Inhibitor<br>Protocol CLCZ696B2314<br>Chronic heart failure and reduced EF.<br>Sub-Investigator |
| 03/2010 -         | Pozen – ASA /omeprazole<br>Protocol PA32540-302<br>Incidence of Gastric Ulcers<br>Sub-Investigator                              |

|           |   |
|-----------|---|
| 07/2010 - | Ortho-McNeil Janssen<br>RIVAROX-AFL-4001<br>Atrial Fibrillation Observational Registry<br>Sub-Investigator            |
| 04/2011   | Novartis – Aliskiren / Valsartan<br>Protocol CSPV100AUS02<br>Hypertension / Type 2 Diabetes<br>Principal Investigator |
| 04/2011   | Novartis – canakinumab<br>Protocol CACZ885M2301<br>Post Myocardial Infarction / elevated hsCRP<br>Sub-Investigator    |
| 11/2011   | Principal Investigator<br>Boston Scientific<br>Multi-SENSE Device Trial   |
| 05/2012   | Amarin<br>Reduce-It Trial<br>Sub-Investigator   |
| 08/2012   | Boehringer Ingleheim<br>GLORIA-AF<br>New Onset Atrial Fibrillation Registry<br>Sub-Investigator                       |
| 08/2012   | Astra Zeneca<br>Ethnicity Study<br>Stable CAD<br>Sub-Investigator   |
| 08/2012   | Takeda<br>EXAMINE<br>Aldogliptin<br>Sub-Investigator  |
| 08/2012   | DCRI / NIH<br>BRIDGE study<br>Principal Investigator  |
| 8/2013    | Boston Scientific<br>LSS of 4-SITE<br>Principal Investigator  |
| 11/2013   | Sub- Investigator<br>Novartis – enalapril – ACE /NEP Inhibitor<br>Protocol CLCZ696B2228<br>TITRATION Trial            |



---

|                   |   |
|-------------------|---|
| 2/2014-Present    | Sub-Investigator<br>NHLBI<br>CIRT Trial   |
| 4/2014-Present    | Principal Investigator<br>Boston Scientific<br>NAVIGATE X4  |
| 4/2014            | Principal Investigator<br>ARCA Biopharma<br>GENETIC-AF  |
| 6/2014            | Principal Investigator<br>Sanofi<br>Multaq Chart Review   |
| 7/2014- Present   | Sub-Investigator<br>Novartis – enalapril – ACE /NEP Inhibitor<br>Protocol CLCZ696D2301<br>PARAGON   |
| 8/2014 - Present  | Sub-Investigator<br>Pfizer / BMS<br>Protocol B0661025 / CB185-267<br>EMANATE  |
| 06/2013 - Present | Sub- Investigator<br>Ortho-McNeil Janssen<br>RIVAROX-AFL-4002<br>ORBIT II - Atrial Fibrillation Observational Registry<br>SATELLITE – Substudy 2015 |
| 06/2015 – Present | Sub- Investigator<br>AstraZeneca<br>D513BC00001<br>THEMIS   |
| 08/2015 – Present | Sub- Investigator<br>Regeneron / DCRI<br>PALM REGISTRY  |
| 08/2015 – Present | Sub- Investigator<br>Pfizer<br>B1481022<br>SPIRE 1 – Hyperlipidemia   |
| 08/2015 – Present | Sub- Investigator<br>Pfizer<br>B1481038<br>SPIRE 2 – Hyperlipidemia   |

01/2016 – Present      Sub- Investigator  
Novartis  
CLCZ696BUS02  
CHAMP-HF

**LICENSURE**

Texas (H5423)

**AFFILIATIONS**

Memorial Hermann Baptist Hospital - Hospital Privileges  
3080 College Street  
Beaumont, Texas 77701

**BIOGRAPHY**

Place of Birth      Nashville, TN  
Date of Birth      May 1, 1961  
Marital Status      Married  
Children      Three